Household & Personal Products · Founded 2004 · www.svendgaard.com · BSE 532771 · NSE JHS SVEN · ISIN INE544H01014
No Notes Added Yet
Business
JHS Svendgaard Laboratories Ltd. is an Indian contract manufacturer and marketer of oral care products. The company primarily operates in two key areas: manufacturing toothpaste, toothbrushes, and mouthwashes for other leading Fast Moving Consumer Goods (FMCG) brands (contract manufacturing/OEM) and developing, manufacturing, and marketing its own range of oral care brands. Its flagship own brands include "aquawhite" (focused on kids' oral care and general segments) and "Smyle" (specialty oral care). The company generates revenue by selling its manufactured products to B2B clients (for contract manufacturing) and directly to consumers through retail channels for its own brands.
Revenue Mix
The company's revenue primarily comes from two streams:
Contract Manufacturing (OEM): Manufacturing oral care products for various national and international FMCG players. This segment has historically been a significant contributor to revenue, leveraging the company's manufacturing capabilities and scale.
Own Brands: Sales of products under its proprietary brands like aquawhite and Smyle. The company has been increasingly focusing on expanding its own brand portfolio and market penetration to drive growth and improve margins.
Industry
The Indian oral care industry is large, growing, and highly competitive, dominated by multinational corporations (e.g., Colgate-Palmolive, Hindustan Unilever) and established domestic players (e.g., Dabur, Patanjali). JHS Svendgaard Laboratories Ltd. is positioned as a niche player. In contract manufacturing, it leverages its modern manufacturing facilities and quality standards to serve a range of clients. For its own brands, particularly aquawhite, it targets specific segments such as kids' oral care, attempting to carve out market share against larger rivals through differentiated offerings and competitive pricing.
MOAT
JHS Svendgaard Laboratories Ltd. possesses a moderate competitive advantage primarily derived from:
Manufacturing Expertise & Scale: Established, modern manufacturing facilities with certifications, enabling efficient, high-quality production for both its own brands and contract manufacturing clients. This provides a cost advantage and reliability.
Client Relationships (B2B): Long-standing relationships with several large FMCG companies for contract manufacturing, indicating trust and established supply chain integration.
Brand Building (Emerging): While not yet a dominant moat, its own brands, especially aquawhite, are gaining recognition in specific segments (like kids' toothbrushes), indicating potential for future brand equity development. Switching costs for consumers in oral care are generally low.
Growth Drivers
Rising Oral Care Penetration: Increasing awareness and disposable incomes in India, especially in semi-urban and rural areas, are driving higher demand for oral care products.
Expansion of Own Brands: Increased marketing, wider distribution network, and new product launches under "aquawhite" and "Smyle" can drive market share gains.
Growth in Contract Manufacturing: As large FMCG companies increasingly outsource production, JHS can capitalize on its established reputation and manufacturing capacity.
Premiumization & Specialization: Growing consumer demand for specialized products (e.g., herbal, sensitive, kids-specific, whitening) offers opportunities for new product development.
Export Opportunities: Leveraging manufacturing capabilities to cater to international markets.
Risks
Intense Competition: The oral care market is highly competitive, making it challenging for JHS to gain significant market share against well-entrenched domestic and international players with larger marketing budgets.
Raw Material Price Volatility: Fluctuations in prices of key raw materials (chemicals, packaging) can impact manufacturing costs and profit margins.
Dependency on Contract Manufacturing Clients: A significant portion of revenue may depend on a few large clients; loss of a major client or renegotiation of terms could adversely affect financials.
Brand Building Challenges: High investment required in marketing and distribution to build and sustain brand equity for its own brands in a crowded market.
Regulatory Changes: Changes in food and drug regulations or quality standards for health and hygiene products could necessitate operational adjustments and increased compliance costs.
Management & Ownership
JHS Svendgaard Laboratories Ltd. is a promoter-led company. The Svendgaard family plays a significant role in the management and strategic direction of the company. Promoter shareholding is typically substantial in such Indian companies, indicating a strong vested interest in the company's long-term performance and growth.
Outlook
JHS Svendgaard Laboratories Ltd. is positioned in a growing essential consumer goods sector in India. The company has a strong foundation in contract manufacturing, which provides a steady revenue stream and leverages its core manufacturing expertise. The strategic focus on expanding its own brands, particularly "aquawhite," presents a significant opportunity for margin improvement and long-term value creation if they can successfully penetrate and build brand loyalty in competitive sub-segments. However, the path to sustained market leadership for its own brands will involve overcoming intense competition from well-established giants, requiring significant ongoing investment in marketing, distribution, and product innovation. Its ability to balance the reliable, but potentially lower-margin, contract manufacturing business with the higher-potential, but riskier, own-brand growth strategy will be key to its future success.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 22 | 24 | 20 | 23 | 25 | 23 | 22 | 23 | 33 | 30 |
| Other Income | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Total Income | 23 | 25 | 21 | 23 | 27 | 24 | 23 | 24 | 33 | 30 |
| Total Expenditure | 21 | 23 | 21 | 22 | 31 | 22 | 21 | 22 | 34 | 28 |
| Operating Profit | 2 | 2 | 0 | 1 | -4 | 3 | 2 | 2 | -1 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -3 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | -2 | -2 | -9 | 1 | -0 | 0 | -3 | 0 |
| Provision for Tax | 1 | 1 | 8 | 0 | -2 | -0 | 0 | -1 | 1 | -1 |
| Profit After Tax | -1 | -1 | -10 | -2 | -7 | 1 | -0 | 1 | -4 | 1 |
| Adjustments | -0 | 0 | -0 | 0 | 0 | 0 | -0 | 0 | -0 | 0 |
| Profit After Adjustments | -1 | -1 | -10 | -2 | -7 | 1 | -0 | 1 | -4 | 1 |
| Adjusted Earnings Per Share | -0.1 | -0.1 | -1.2 | -0.2 | -0.8 | 0.1 | -0 | 0.1 | -0.4 | 0.1 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 100 | 105 | 140 | 124 | 139 | 101 | 86 | 85 | 71 | 92 | 102 | 108 |
| Other Income | 1 | 0 | 5 | 7 | 14 | 8 | 9 | 11 | 4 | 3 | 3 | 3 |
| Total Income | 101 | 105 | 145 | 131 | 153 | 108 | 96 | 96 | 75 | 95 | 105 | 110 |
| Total Expenditure | 94 | 93 | 127 | 125 | 137 | 99 | 87 | 94 | 72 | 96 | 99 | 105 |
| Operating Profit | 7 | 12 | 19 | 6 | 16 | 9 | 9 | 2 | 3 | -1 | 6 | 5 |
| Interest | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Depreciation | 10 | 6 | 7 | 7 | 9 | 7 | 7 | 6 | 6 | 8 | 7 | 8 |
| Exceptional Income / Expenses | -18 | -0 | 27 | 0 | -11 | 0 | 0 | -19 | 0 | -3 | 0 | 0 |
| Profit Before Tax | -22 | 5 | 38 | -2 | -6 | 1 | 0 | -23 | -3 | -13 | -2 | -3 |
| Provision for Tax | 0 | -17 | 12 | -0 | -1 | -0 | 4 | -5 | 1 | 7 | -0 | -1 |
| Profit After Tax | -22 | 22 | 26 | -2 | -5 | 1 | -4 | -18 | -4 | -20 | -2 | -2 |
| Adjustments | 0 | 0 | 0 | 1 | 3 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -22 | 22 | 26 | -1 | -2 | 1 | -4 | -17 | -4 | -20 | -2 | -2 |
| Adjusted Earnings Per Share | -5.7 | 5 | 4.3 | -0.1 | -0.3 | 0.2 | -0.6 | -2.2 | -0.5 | -2.3 | -0.2 | -0.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 11% | 6% | 0% | 0% |
| Operating Profit CAGR | 0% | 44% | -8% | -2% |
| PAT CAGR | 0% | 0% | NAN% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -26% | -26% | -18% | -12% |
| ROE Average | -1% | -5% | -5% | -1% |
| ROCE Average | -1% | -3% | -4% | -1% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 101 | 134 | 174 | 177 | 178 | 189 | 186 | 174 | 170 | 173 | 175 |
| Minority's Interest | 0 | -0 | -0 | 4 | 7 | 9 | 9 | 0 | 0 | 0 | 0 |
| Borrowings | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 6 |
| Other Non-Current Liabilities | 1 | -16 | -4 | -4 | -3 | -4 | 1 | 6 | -7 | -0 | -2 |
| Total Current Liabilities | 18 | 20 | 32 | 39 | 48 | 23 | 19 | 37 | 23 | 25 | 33 |
| Total Liabilities | 121 | 138 | 203 | 216 | 230 | 218 | 215 | 217 | 187 | 198 | 211 |
| Fixed Assets | 65 | 65 | 71 | 71 | 66 | 63 | 59 | 65 | 90 | 90 | 89 |
| Other Non-Current Assets | 20 | 31 | 29 | 44 | 34 | 23 | 77 | 67 | 52 | 54 | 58 |
| Total Current Assets | 36 | 43 | 103 | 102 | 130 | 121 | 79 | 85 | 44 | 53 | 63 |
| Total Assets | 121 | 138 | 203 | 216 | 230 | 218 | 215 | 217 | 187 | 198 | 211 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 3 | 6 | 6 | 1 | 1 | 21 | 5 | 37 | 9 | 7 |
| Cash Flow from Operating Activities | -4 | -4 | 14 | -11 | 10 | 12 | -9 | 23 | -9 | -5 | -3 |
| Cash Flow from Investing Activities | 1 | -3 | -27 | -7 | -11 | -2 | -5 | 10 | -21 | -20 | -12 |
| Cash Flow from Financing Activities | 4 | 10 | 14 | 13 | 0 | 10 | -2 | -1 | 2 | 23 | 11 |
| Net Cash Inflow / Outflow | 2 | 3 | 0 | -5 | -0 | 20 | -16 | 32 | -28 | -2 | -3 |
| Closing Cash & Cash Equivalent | 3 | 6 | 6 | 1 | 1 | 21 | 5 | 37 | 9 | 7 | 4 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -5.75 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | -2.2 | -0.52 | -2.31 | -0.22 |
| CEPS(Rs) | -2.96 | 6.41 | 5.4 | 0.89 | 0.64 | 1.33 | 0.43 | -1.47 | 0.29 | -1.38 | 0.64 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 25.2 | 29.41 | 28.58 | 28.97 | 29.16 | 27.56 | 28.6 | 22.16 | 21.67 | 19.88 | 19.98 |
| Core EBITDA Margin(%) | 6.42 | 11.13 | 9.64 | -0.47 | 1.19 | 1.9 | -0.98 | -10.7 | -1.32 | -4.36 | 2.57 |
| EBIT Margin(%) | -21.26 | 5.48 | 27.46 | -0.81 | -2.78 | 2.19 | 1.74 | -26.41 | -4.19 | -12.98 | -1.41 |
| Pre Tax Margin(%) | -21.62 | 4.89 | 26.94 | -1.65 | -4.17 | 0.96 | 0.12 | -27.05 | -4.84 | -13.6 | -2.25 |
| PAT Margin (%) | -21.62 | 20.88 | 18.27 | -1.34 | -3.47 | 1.33 | -4.97 | -20.65 | -5.73 | -21.46 | -1.89 |
| Cash Profit Margin (%) | -11.14 | 26.93 | 23.04 | 4.36 | 2.79 | 8.52 | 3.2 | -13.56 | 3.23 | -12.82 | 5.48 |
| ROA(%) | -14.88 | 16.91 | 15.25 | -0.79 | -2.17 | 0.6 | -1.98 | -8.11 | -2.01 | -10.27 | -0.94 |
| ROE(%) | -20.17 | 19.53 | 17.15 | -0.95 | -2.74 | 0.76 | -2.36 | -9.75 | -2.36 | -11.61 | -1.12 |
| ROCE(%) | -17.59 | 4.8 | 25.01 | -0.56 | -2.15 | 1.24 | 0.82 | -12.43 | -1.71 | -6.8 | -0.78 |
| Receivable days | 58.65 | 35.73 | 72.14 | 141.83 | 195.53 | 280.04 | 162.56 | 78.87 | 80.98 | 51.46 | 53.5 |
| Inventory Days | 33.41 | 34.81 | 25.93 | 27.26 | 19.07 | 31.19 | 50.23 | 54.01 | 66.11 | 48.67 | 48.54 |
| Payable days | 105.68 | 122.24 | 120.92 | 134.03 | 145.67 | 208.84 | 139.67 | 166.85 | 237.71 | 143.68 | 152.49 |
| PER(x) | 0 | 7.86 | 12.49 | 0 | 0 | 107.2 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0.89 | 1.33 | 1.88 | 0.95 | 0.26 | 0.72 | 0.72 | 0.71 | 0.76 | 0.56 | 0.32 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.84 | 1.61 | 2.3 | 1.4 | 0.33 | 1.07 | 1.48 | 1 | 1.72 | 0.88 | 0.5 |
| EV/Core EBITDA(x) | 11.78 | 13.96 | 17.24 | 28.67 | 2.93 | 11.43 | 14.93 | 37.75 | 36.03 | -71.69 | 8.46 |
| Net Sales Growth(%) | 80.91 | 4.97 | 33.54 | -11.53 | 12.09 | -27.57 | -14.4 | -1.67 | -16.53 | 29.94 | 10.54 |
| EBIT Growth(%) | 3.26 | 127.05 | 580.55 | -102.58 | -284.7 | 156.75 | -32.21 | -1596.63 | 86.75 | -302.38 | 88.03 |
| PAT Growth(%) | 2.42 | 201.36 | 18.78 | -106.4 | -191.19 | 127.65 | -419.53 | -308.38 | 76.84 | -386.59 | 90.26 |
| EPS Growth(%) | 37.52 | 186.69 | -13.79 | -102.6 | -190.7 | 157.26 | -435.46 | -253.05 | 76.52 | -345.61 | 90.47 |
| Debt/Equity(x) | 0.03 | 0.02 | 0.01 | 0.04 | 0 | 0 | 0 | 0 | 0.02 | 0.03 | 0.08 |
| Current Ratio(x) | 1.94 | 2.16 | 3.24 | 2.63 | 2.69 | 5.23 | 4.18 | 2.31 | 1.87 | 2.16 | 1.95 |
| Quick Ratio(x) | 1.44 | 1.64 | 2.99 | 2.49 | 2.61 | 4.73 | 3.54 | 1.96 | 1.33 | 1.68 | 1.48 |
| Interest Cover(x) | -58.32 | 9.31 | 52.83 | -0.98 | -1.99 | 1.78 | 1.07 | -40.98 | -6.44 | -21.14 | -1.66 |
| Total Debt/Mcap(x) | 0.03 | 0.01 | 0.01 | 0.04 | 0.02 | 0.01 | 0.01 | 0 | 0.03 | 0.05 | 0.27 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 37.73 | 37.73 | 34.56 | 34.56 | 34.56 | 34.56 | 34.56 | 34.56 | 33.85 | 33.85 |
| FII | 2.3 | 0.15 | 1.69 | 1.59 | 1.6 | 1.59 | 1.57 | 1.57 | 3.6 | 3.14 |
| DII | 6.21 | 6.05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 53.76 | 56.07 | 63.75 | 63.85 | 63.84 | 63.85 | 63.87 | 63.87 | 62.56 | 63.01 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 |
| FII | 0.18 | 0.01 | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 | 0.13 | 0.31 | 0.27 |
| DII | 0.49 | 0.47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 4.21 | 4.4 | 5.46 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7.84 | 7.84 | 8.56 | 8.56 | 8.56 | 8.56 | 8.56 | 8.56 | 8.74 | 8.74 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +11% | +6% | 0% | 0% |
| Operating Profit CAGR | — | +44% | -8% | -2% |
| PAT CAGR | — | — | 0% | — |
| Share Price CAGR | -26% | -26% | -18% | -12% |
| ROE Average | -1% | -5% | -5% | -1% |
| ROCE Average | -1% | -3% | -4% | -1% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 37.73 | 37.73 | 34.56 | 34.56 | 34.56 | 34.56 | 34.56 | 34.56 | 33.85 | 33.85 |
| FII | 2.3 | 0.15 | 1.69 | 1.59 | 1.6 | 1.59 | 1.57 | 1.57 | 3.6 | 3.14 |
| DII | 6.21 | 6.05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 53.76 | 56.07 | 63.75 | 63.85 | 63.84 | 63.85 | 63.87 | 63.87 | 62.56 | 63.01 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 | 2.96 |
| FII | 0.18 | 0.01 | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 | 0.13 | 0.31 | 0.27 |
| DII | 0.49 | 0.47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 4.21 | 4.4 | 5.46 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7.84 | 7.84 | 8.56 | 8.56 | 8.56 | 8.56 | 8.56 | 8.56 | 8.74 | 8.74 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.